BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates February 27, 2026
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs January 9, 2026
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium December 12, 2025
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) November 3, 2025
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 24, 2025
